BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21130025)

  • 1. Prognostic value of tissue polypeptide antigen in oral squamous cell carcinoma.
    Sawant SS; Chaukar DA; Joshi SS; Dange PP; Kannan S; Kane S; D'Cruz AK; Vaidya MM
    Oral Oncol; 2011 Feb; 47(2):114-20. PubMed ID: 21130025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic value of tissue polypeptide antigen in serum of larynx cancer patients].
    Polberg K; Stepulak A; Stryjecka-Zimmer M; Kupisz K; Zawiślak J
    Pol Merkur Lekarski; 2005 Oct; 19(112):517-20. PubMed ID: 16379315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin fragments in the serum: their utility for the management of oral cancer.
    Sawant SS; Zingde SM; Vaidya MM
    Oral Oncol; 2008 Aug; 44(8):722-32. PubMed ID: 18203649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix.
    Ngan HY; Cheng GT; Yeung WS; Wong LC; Ma HK
    Gynecol Oncol; 1994 Jan; 52(1):63-8. PubMed ID: 8307503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
    Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
    Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification in oral cavity squamous cell carcinoma by preoperative CRP and SCC antigen levels.
    Huang SF; Wei FC; Liao CT; Wang HM; Lin CY; Lo S; Huang JJ; Chen IH; Kang CJ; Chien HT; Chen HH
    Ann Surg Oncol; 2012 Nov; 19(12):3856-64. PubMed ID: 22576068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
    Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
    Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
    Shang ZJ; Li JR; Li ZB
    Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tissue polypeptide antigen (TPA): monoclonal or polyclonal radio-immunometric assay for the follow-up of bladder cancer.
    Bennink R; Van Poppel H; Billen J; Decoster M; Baert L; Mortelmans L; Blanckaert N
    Anticancer Res; 1999; 19(4A):2609-13. PubMed ID: 10470203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tissue polypeptide specific antigen as a noninvasive prognostic indicator for early recurrence of hepatocellular carcinoma after curative resection.
    Yao WJ; Wang ST; Chow NH; Chang TT; Lin PW; Tu DG
    Cancer; 2002 Jul; 95(1):112-8. PubMed ID: 12115324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of tissue polypeptide antigen (TPA) plasma levels in patients with malignant salivary gland tumors.
    Tanany H; Ezz M; Yassin S
    Egypt Dent J; 1993 Jul; 39(3):505-6. PubMed ID: 9590978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue polypeptide antigen in bronchogenic carcinoma.
    Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O
    Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haematogenous cytokeratin 20 mRNA as a predictive marker for recurrence in oral cancer patients.
    Kawamata H; Uchida D; Nakashiro K; Hino S; Omotehara F; Yoshida H; Sato M
    Br J Cancer; 1999 May; 80(3-4):448-52. PubMed ID: 10408852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients.
    Zhong LP; Zhang CP; Zheng JW; Li J; Chen WT; Zhang ZY
    Arch Oral Biol; 2007 Nov; 52(11):1079-87. PubMed ID: 17612501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
    Ecke TH; Lenk SV; Schlechte HH; Loening SA
    Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.